Eli Lilly (LLY) Other financing activities (2009 - 2026)

Eli Lilly has reported Other financing activities for 16 years, with the latest figure at -$591.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 13.85% year-over-year to -$591.0 million; the trailing twelve-month figure through Mar 2026 stood at -$677.0 million (up 14.0% YoY), and the FY2025 full-year result was -$772.0 million, down 57.23% from the prior year.
• Other financing activities for Q1 2026 stood at -$591.0 million, down from -$25.1 million in the prior quarter.
• The five-year high for Other financing activities was -$5.2 million in Q3 2022, with the low at -$686.0 million in Q1 2025.
• Historically, Other financing activities has averaged -$146.9 million across 5 years, with a median of -$30.7 million in 2025.
• The largest YoY upside for Other financing activities was 48.99% in 2022 against a maximum downside of 2183.33% in 2022.
• Eli Lilly's Other financing activities stood at -$13.7 million in 2022, then sank by 130.66% to -$31.6 million in 2023, then sank by 45.25% to -$45.9 million in 2024, then soared by 45.32% to -$25.1 million in 2025, then tumbled by 2254.58% to -$591.0 million in 2026.
• The last three Other financing activities figures came in at -$591.0 million (Q1 2026), -$25.1 million (Q4 2025), and -$30.2 million (Q3 2025), per Business Quant data.